Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

被引：0
|
作者：
Koji Izutsu
Michinori Ogura
Kensei Tobinai
Kiyohiko Hatake
Shigeru Sakamoto
Masanori Nishimura
Miyako Hoshino
机构：
[1] National Cancer Center Hospital,Department of Hematology
[2] Toranomon Hospital,Department of Hematology
[3] Kasugai Municipal Hospital,Department of Hematology/Oncology
[4] International University of Health and Welfare (IUHW) School of Medicine,Department of Hematology
[5] The Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Hematology and Oncology
[6] Takeda Pharmaceutical Co. Ltd.,Japan Medical Office, Japan Pharma Business Unit
[7] Takeda Pharmaceutical Co. Ltd.,Pharmacovigilance, Takeda Development Center Japan
来源：
International Journal of Hematology | 2021年 / 113卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original article can be found online.
引用
收藏
页码：611 / 611
相关论文
共 50 条
  • [1] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
    Izutsu, Koji
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Sakamoto, Shigeru
    Nishimura, Masanori
    Hoshino, Miyako
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 404 - 412
  • [2] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
    Koji Izutsu
    Michinori Ogura
    Kensei Tobinai
    Kiyohiko Hatake
    Shigeru Sakamoto
    Masanori Nishimura
    Miyako Hoshino
    International Journal of Hematology, 2021, 113 : 404 - 412
  • [3] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (vol 113, pg 404, 2021)
    Izutsu, Koji
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Sakamoto, Shigeru
    Nishimura, Masanori
    Hoshino, Miyako
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (04) : 611 - 611
  • [4] Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya M.
    Gibb, Adam
    Grove, Laurie E.
    Advani, Ranjana
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 703 - 710
  • [5] Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Vaklavas, Christos
    Forero-Torres, Andres
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 209 - 225
  • [6] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [7] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Ishizawa, Kenichi
    Yanai, Tomoko
    ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
  • [8] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [9] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [10] THE ARROVEN STUDY (MA25101): POST-AUTHORISATION OBSERVATIONAL SAFETY STUDY OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA
    Linton, K.
    Ayto, R.
    d'Amore, F.
    Moestl, M.
    Chau, I.
    Paneesha, S.
    Kinley, J.
    Huebner, D.
    Porter, J.
    Exter, B.
    Wang, B.
    Tymoszczuk, J.
    Arumainathan, A.
    HAEMATOLOGICA, 2015, 100 : 455 - 455
12345